TY - JOUR
T1 - Nationwide analysis of hospital variation in preoperative radiotherapy use for rectal cancer following guideline revision
AU - Detering, Robin
AU - de Nerée tot Babberich, Michael P.M.
AU - the Dutch ColoRectal Audit
AU - Bos, Amanda C.R.K.
AU - Dekker, Jan Willem T.
AU - Wouters, Michel W.J.M.
AU - Bemelman, Willem A.
AU - Beets-Tan, Regina G.H.
AU - Marijnen, Corrie A.M.
AU - Hompes, Roel
AU - Tanis, Pieter J.
AU - Coene, Peter-Paul
AU - Doornebosch, P. G.
AU - Manusama, E. R.
AU - Wagner, A.
N1 - Publisher Copyright: © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
PY - 2020/3
Y1 - 2020/3
N2 - Introduction: The revised Dutch colorectal cancer guideline (2014), led to an overall decrease in preoperative radiotherapy (RT) use. This study evaluates hospital variation in RT use for resectable rectal cancer and the influence of guideline revision, including the nationwide impact of changing RT application on short term outcomes. Methods: Data of surgically resected rectal cancer patients registered in the Dutch ColoRectal Audit were extracted between 2011 and 2017. Patients were divided into groups based on time of guideline revision (<2014 and ≥ 2014). Primary outcome was guideline adherence at hospital level regarding RT application, stratified for three stage groups. Secondary outcomes included positive circumferential resection (CRM+) and 30-day complicated postoperative course. Results: The groups consisted of 7364 and 12,057 patients, respectively. In total, 6772 patients did not receive RT (17.6% vs. 45.7%. The largest increase of surgery alone was observed for cT1-2N0 stage rectal cancer, with a substantial decrease in hospital variation. For cT1-3N1MRF- stage rectal cancer, a substantial amount of hospital variation in short course RT remained after guideline revision. A significant decrease in CRM+ and complicated course was observed. Conclusions: Radiotherapy for early-stage rectal cancer was uniformly abandoned after guideline revision, while substantial hospital variation remained for intermediate risk resectable rectal cancer in the Netherlands. The substantial nationwide decrease in the use of RT for rectal cancer treatment did not negatively impact CRM involvement.
AB - Introduction: The revised Dutch colorectal cancer guideline (2014), led to an overall decrease in preoperative radiotherapy (RT) use. This study evaluates hospital variation in RT use for resectable rectal cancer and the influence of guideline revision, including the nationwide impact of changing RT application on short term outcomes. Methods: Data of surgically resected rectal cancer patients registered in the Dutch ColoRectal Audit were extracted between 2011 and 2017. Patients were divided into groups based on time of guideline revision (<2014 and ≥ 2014). Primary outcome was guideline adherence at hospital level regarding RT application, stratified for three stage groups. Secondary outcomes included positive circumferential resection (CRM+) and 30-day complicated postoperative course. Results: The groups consisted of 7364 and 12,057 patients, respectively. In total, 6772 patients did not receive RT (17.6% vs. 45.7%. The largest increase of surgery alone was observed for cT1-2N0 stage rectal cancer, with a substantial decrease in hospital variation. For cT1-3N1MRF- stage rectal cancer, a substantial amount of hospital variation in short course RT remained after guideline revision. A significant decrease in CRM+ and complicated course was observed. Conclusions: Radiotherapy for early-stage rectal cancer was uniformly abandoned after guideline revision, while substantial hospital variation remained for intermediate risk resectable rectal cancer in the Netherlands. The substantial nationwide decrease in the use of RT for rectal cancer treatment did not negatively impact CRM involvement.
UR - http://www.scopus.com/inward/record.url?scp=85076832973&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2019.12.016
DO - 10.1016/j.ejso.2019.12.016
M3 - Article
C2 - 31882252
AN - SCOPUS:85076832973
SN - 0748-7983
VL - 46
SP - 486
EP - 494
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 3
ER -